Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker (NYSE:SYK) launched the SmartHospital Platform on March 9, 2026, a digital foundation to connect devices, data and care teams into one adaptive hospital ecosystem.
Key features include connected infrastructure, clinical communication (Sync Badge), the Engage workflow engine, virtual care and ambient intelligence to streamline operations and support bedside staff.
Stryker (NYSE: SYK) highlighted new orthopaedic product advances at the AAOS 2026 Annual Meeting on March 3, 2026, including Triathlon Gold (titanium nitride femoral component), a Triathlon Medial Stabilized insert, full market release of Mako Shoulder, Mako RPS handheld robotics, and new power tools BPX and TPX HD.
Attendees can view demos and symposiums at booth #3339.
Stryker (NYSE:SYK) launched Synchfix EVT, a next‑generation flexible syndesmotic fixation device designed to simplify surgical deployment and support ankle stabilization for adults and adolescents. The all‑in‑one system integrates suture tensioning handles, enables one‑handed implant deployment, and uses a low‑profile titanium medial implant. Synchfix EVT is the first flexible ankle syndesmotic fixation device indicated for adolescents and earned a Red Dot Design Award. Stryker is showcasing the sterile, single‑use, knotless, flexible suture‑button system at the 2026 ACFAS Annual Meeting with demonstrations highlighting procedural efficiency.
Stryker (NYSE: SYK) launched the T2 Alpha Humerus Nailing System on February 11, 2026, adding to its T2 Alpha portfolio.
The system uses SOMA-informed design from CT data to improve anatomical fit, offers up to 6mm active intraoperative compression, multiplanar locking screws, and guided targeting to streamline humerus fracture fixation and OR workflow.
Stryker (NYSE: SYK) announced the limited market release of Mako RPS (Robotic Power System) for Total Knee, introducing Mako Handheld Robotics as an expansion of the Mako family. Mako RPS integrates an intraoperative planner and a robotically enabled saw compatible with Triathlon Total Knee and Q Guidance System.
The system offers active adjustment technology that guides a surgeon's saw to align with the surgical plan and aims to fit into existing workflows without cutting blocks. Stryker will demonstrate Mako SmartRobotics and Mako Handheld Robotics at AAOS 2026, booth #3339.
Stryker (NYSE:SYK) declared a quarterly cash dividend of $0.88 per share, payable April 30, 2026, to shareholders of record at the close of business on March 31, 2026.
The dividend equals the prior quarter and represents a 4.8% increase year-over-year, reflecting steady shareholder distributions.
Stryker (NYSE:SYK) reported strong fourth-quarter and full-year 2025 operating results: Q4 net sales $7.17B (+11.4%), full-year net sales $25.12B (+11.2%), organic growth Q4 +11.0% and FY +10.3%. Adjusted operating margin expanded +100 bps to 30.2% (Q4) and 26.3% (FY). 2026 outlook: organic sales growth of 8.0%–9.5% and adjusted EPS of $14.90–$15.10.
Cash flow from operations was $5.04B; acquisitions spending was $4.96B in 2025. Management cites strong capital-product demand and procedural volumes entering 2026.
VB Spine completed the acquisition of Stryker's spine implant manufacturing facility in Cestas, France on January 6, 2026, expanding its global manufacturing footprint.
The Cestas site, including its people, infrastructure, and processes, will anchor VB Spine's worldwide manufacturing strategy and support expanded medical education and training programs in Europe. Employees transitioned from Stryker to VB Spine and manufacturing operations continue without interruption. Integration planning is underway to align systems, quality, and supply chain.
Stryker (NYSE:SYK) will report fourth quarter and full year 2025 financial results on Thursday, January 29, 2026. A press release with summary financial information for the period ended December 31, 2025 will be issued at approximately 4:05 p.m. ET and posted to the company's press releases page.
Stryker will host a live webcast at 4:30 p.m. ET on January 29, 2026 to discuss results; the webcast is accessible on the company's Events & Presentations page and an archive will be available about two hours after the call ends.
Stryker (NYSE:SYK) announced a quarterly dividend of $0.88 per share, payable January 30, 2026 to shareholders of record at the close of business on December 31, 2025. The Board said the payout represents a 4.8% increase versus both the prior year and the previous quarter. Management framed the raise as consistent with the company’s capital allocation priorities and confidence in future financial performance.